Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL84 single ascending dose study in healthy volunteers
NCT06217952Phase 1Completed
- Sponsor
- SpliSense
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing SPL84 with Placebo (2 arms). Primary endpoints: Adverse Events, Vital Signs Abnormalities and 5 more. Started Feb 2023; status: completed.
02
Drugs
SPL84
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06217952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217952.